Yanling Cao

Mar 31, 2021View PDF

Mr. Cao is primarily responsible for participating in formulating our Company’s corporate and business strategies.


Mr. Cao has over ten years of experience in private equity investment and management. From December 2007 to January 2011, he served as an investment associate at General Atlantic Asia Limited, a company primarily engaged in private equity and venture capital investment, and was responsible for development, execution and management of equity investment. Mr. Cao has been the managing director of Boyu Capital Advisory Company Limited since March 2011 and currently serves as a partner, mainly responsible for investments in the healthcare industry. Mr. Cao served as a director of CStone Pharmaceuticals from April 2016 to March 2017 and has been a non-executive director since May 2019. He has been a director of Hygeia Healthcare Holdings Co., Limited since June 2019 and has been a non-executive director since September 2019. He has also been a non-executive director of WuXi Biologics (Cayman) Inc. since May 2016, Viela Bio, Inc. since February 2018 and Ocumension Therapeutics since June 2019.


Mr. Cao has also been a director of Antengene Zhejiang since January 2019. Mr. Cao obtained his Bachelor’s degree in economics and mathematics from Middlebury College in the United States in May 2006.